{"id":"tozinameran-12-years-of-age-and-older","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Live, intranasal influenza vaccines","action":"Avoid","effect":"May diminish the therapeutic effect of Tozinameran"},{"drug":"Live vaccines","action":"Avoid","effect":"May diminish the therapeutic effect of Tozinameran"},{"drug":"Other vaccines","action":"Avoid","effect":"May diminish the therapeutic effect of Tozinameran"},{"drug":"Thrombolytic agents","action":"Monitor","effect":"May enhance the adverse/toxic effect of Thrombolytic agents"},{"drug":"Warfarin","action":"Monitor","effect":"May enhance the anticoagulant effect of Warfarin"},{"drug":"Anticoagulants","action":"Monitor","effect":"May enhance the anticoagulant effect of Anticoagulants"},{"drug":"Antiplatelet agents","action":"Monitor","effect":"May enhance the antiplatelet effect of Antiplatelet agents"},{"drug":"Immunosuppressives","action":"Monitor","effect":"May enhance the immunosuppressive effect of Immunosuppressives"},{"drug":"Live, oral influenza vaccines","action":"Avoid","effect":"May diminish the therapeutic effect of Tozinameran"}],"commonSideEffects":[],"contraindications":["History of a severe allergic reaction* (e.g., anaphylaxis†) after a previous dose or to a vaccine component","Administration error/deviation Interim recommendation recipient age 12 years and older"],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"Safety and efficacy have not been established in patients younger than 12 years; an EUA is in effect for the use of an experimental vaccine to prevent COVID-19 in patients 12 through 15 years of age; this drug is not authorized for use in patients younger than 12 years.","Renal impairment":"Data not available","Hepatic impairment":"Data not available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tozinameran-12-years-of-age-and-older","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:30:53.677698+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:31:00.009610+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:30:53.749421+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tozinameran-12-years-of-age-and-older","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:31:00.406765+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Spike glycoprotein vaccine antigen","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:01.912312+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650429/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:01.576480+00:00"}},"allNames":"tozinameran 12 years of age and older","offLabel":[],"timeline":[],"aiSummary":"Tozinameran, developed by Pfizer Inc., is a COVID-19 vaccine for individuals 12 years of age and older. It works by stimulating the body's immune system to produce antibodies against the SARS-CoV-2 virus. The key indication is the prevention of COVID-19. Tozinameran has clinical differentiation due to its effectiveness in preventing severe illness and hospitalization. It has significant commercial value, generating $21.2B in revenue. There are no notable pipeline developments for this drug.","brandName":"Tozinameran 12 Years of age and older","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein","novelty":"first-in-class","modality":"mRNA","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"Tozinameran is a mRNA-based vaccine that uses a piece of genetic material called messenger RNA to instruct cells to produce a protein from the SARS-CoV-2 virus. This protein is then recognized by the immune system, which mounts a response to produce antibodies against the virus."},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tozinameran-12-years-of-age-and-older","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tozinameran-12-years-of-age-and-older","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:28:38.801614+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Riltozinameran","company":"Pfizer","advantage":"Combines with Tozinameran for protection against BA.4-5 as well as BA.1"},{"name":"Famtozinameran","company":"Pfizer","advantage":"Combines with Tozinameran for protection against BA.1 as well as BA.4-5"}],"genericName":"tozinameran-12-years-of-age-and-older","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000}],"_emaApprovals":[{"date":"","name":"Tozinameran 12 Years of age and older","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4650429","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL4650429"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-01 10:46:06.083601+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_revenueClearedDupe":"famtozinameran-12-years-of-age-and-older","_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"mRNA","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:28:38.801614+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}